Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Gossamer Bio (GOSS) Share-based Compensation (2022 - 2025)

Gossamer Bio (GOSS) has 4 years of Share-based Compensation data on record, last reported at $2.7 million in Q3 2025.

  • For Q3 2025, Share-based Compensation fell 44.94% year-over-year to $2.7 million; the TTM value through Sep 2025 reached $12.6 million, down 41.8%, while the annual FY2024 figure was $20.6 million, 27.7% down from the prior year.
  • Share-based Compensation reached $2.7 million in Q3 2025 per GOSS's latest filing, up from $2.6 million in the prior quarter.
  • Across five years, Share-based Compensation topped out at $11.4 million in Q4 2022 and bottomed at $2.4 million in Q1 2025.
  • Average Share-based Compensation over 4 years is $6.6 million, with a median of $6.0 million recorded in 2023.
  • Peak YoY movement for Share-based Compensation: decreased 17.69% in 2024, then tumbled 58.61% in 2025.
  • A 4-year view of Share-based Compensation shows it stood at $11.4 million in 2022, then plummeted by 47.31% to $6.0 million in 2023, then fell by 17.69% to $5.0 million in 2024, then tumbled by 46.3% to $2.7 million in 2025.
  • Per Business Quant database, its latest 3 readings for Share-based Compensation were $2.7 million in Q3 2025, $2.6 million in Q2 2025, and $2.4 million in Q1 2025.